Digital Biomarkers & Clinical Measures in Neurology Summit starts in...
*Please note tickets for service providers have now sold out.
More Objectively, Frequently & Sensitively Diagnose & Monitor Patients to Robustly Prove Drug Efficacy in Neurological Trials
Critical advances in device design, data collection, and algorithm development are redefining the landscape for integrating digital technologies into neurological clinical trials to monitor disease progression, establish therapeutic efficacy, and aid diagnosis. In the context of inherent disease complexity and vast heterogeneity across populations leading to the industry’s highest clinical failure rate, industry progress needs a biomarker revolution to take the next step in bringing meaningful treatment options to patients, but what are the next steps in developing, integrating, and validating digital biomarkers in neurological trials?
Uniting industry experts dedicated to implementing digital biomarkers in Neurodegenerative, Movement and Neuropsychiatric Disorders clinical trials, the Digital Biomarkers & Clinical Measures in Neurology Summit is the definitive industry forum sharing cross-industry insight to transform clinical development with digital data.
From integrating wearable technologies, smartphone apps, and speech-based digital biomarkers into remote clinical research to elucidating pathways to clinical validation to establish therapeutic efficacy, join industry experts from Merck, Janssen, GSK, Sanofi, Novartis, Takeda, Eli Lilly & Company, Mitsubishi Tanabe Pharma Holdings America and many more to improve patient retention and establish efficacy with richer datasets.